Pande Shripad B, Doval D C, Pavithran K, Sharma J B, Shirali Rashmi, Jena A
Department of Medical Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India.
Indian J Med Paediatr Oncol. 2012 Jan;33(1):42-7. doi: 10.4103/0971-5851.96968.
Gemcitabine, an anti-metabolite, has some activity in hepatocellular carcinoma (HCC) in terms of responses and median survival.
To analyze our experience with the use of gemcitabine in combination with cisplatin in HCC with respect to response, toxicity and survival.
We studied the records of patients of HCC treated from January 2000 to December 2005 with gemcitabine and cisplatin, and found 24 of them to be evaluable for response, toxicity and survival.
Of 24 patients receiving three or more cycles of chemotherapy, six (25%) had a partial response and an additional 12 (50%) had stable disease. The median overall survival (OS) was 7.5 months (95% confidence interval, 4.5-10.5 months) and 1-year survival was 18%. Grade 3 and 4 anemia, thrombocytopenia and neutropenia were observed in, respectively, 17, 17 and 33% patients. The most frequent non-hematologic toxicities were nausea and vomiting and peripheral neuropathy.
We report a partial response rate of 25% with stable disease in an additional 50% to three or more cycles of chemotherapy with gemcitabine and cisplatin, with a median OS of 7.5 months (95% confidence interval, 4.5-10.5) and acceptable toxicity profile from our single-center retrospective study of 24 patients of HCC. We trust that, in HCC, gemcitabine is a good drug to be the foundation to build the chemotherapeutic or targeted agents' combinations on.
吉西他滨是一种抗代谢药物，在肝细胞癌（HCC）的反应和中位生存期方面具有一定活性。
分析我们使用吉西他滨联合顺铂治疗HCC的经验，包括反应、毒性和生存期。
我们研究了2000年1月至2005年12月接受吉西他滨和顺铂治疗的HCC患者的记录，发现其中24例可评估反应、毒性和生存期。
在接受三个或更多周期化疗的24例患者中，6例（25%）有部分反应，另外12例（50%）病情稳定。中位总生存期（OS）为7.5个月（95%置信区间，4.5 - 10.5个月），1年生存率为18%。分别有17%、17%和33%的患者出现3级和4级贫血、血小板减少和中性粒细胞减少。最常见的非血液学毒性是恶心、呕吐和周围神经病变。
我们通过对24例HCC患者的单中心回顾性研究报告，吉西他滨联合顺铂进行三个或更多周期化疗的部分反应率为25%，另外50%病情稳定，中位OS为7.5个月（95%置信区间，4.5 - 10.5），毒性可接受。我们相信，在HCC治疗中，吉西他滨是构建化疗或靶向药物联合方案的良好基础药物。
